Literature DB >> 18956467

Susceptibility weighted imaging at ultra high magnetic field strengths: theoretical considerations and experimental results.

Andreas Deistung1, Alexander Rauscher, Jan Sedlacik, Jörg Stadler, Stephan Witoszynskyj, Jürgen R Reichenbach.   

Abstract

We present numerical simulations and experimental results for susceptibility weighted imaging (SWI) at 7 T. Magnitude, phase, and SWI contrast were simulated for different voxel geometries and imaging parameters, resulting in an echo time of 14 msec for optimum contrast between veins and surrounding tissue. Slice thickness of twice the in-plane voxel size or more resulted in optimum vessel visibility. Phantom and in vivo data are in very good agreement with the simulations and the delineation of vessels at 7 T was superior compared to lower field strengths. The phase of the complex data reveals anatomical details that are complementary to the corresponding magnitude images. Susceptibility weighted imaging at very high field strengths is a promising technique because of its high sensitivity to tissue susceptibility, its low specific absorption rate, and the phase's negligible sensitivity to B(1) inhomogeneities.

Mesh:

Year:  2008        PMID: 18956467     DOI: 10.1002/mrm.21754

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  52 in total

1.  The contribution of chemical exchange to MRI frequency shifts in brain tissue.

Authors:  Karin Shmueli; Stephen J Dodd; Tie-Qiang Li; Jeff H Duyn
Journal:  Magn Reson Med       Date:  2011-01       Impact factor: 4.668

2.  Ultra-high-field magnetic resonance: Why and when?

Authors:  Ewald Moser
Journal:  World J Radiol       Date:  2010-01-28

Review 3.  The future of ultra-high field MRI and fMRI for study of the human brain.

Authors:  Jeff H Duyn
Journal:  Neuroimage       Date:  2011-10-28       Impact factor: 6.556

4.  Heterogeneity of Cortical Lesion Susceptibility Mapping in Multiple Sclerosis.

Authors:  M Castellaro; R Magliozzi; A Palombit; M Pitteri; E Silvestri; V Camera; S Montemezzi; F B Pizzini; A Bertoldo; R Reynolds; S Monaco; M Calabrese
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

5.  Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma.

Authors:  Ulrike Löbel; Jan Sedlacik; Noah D Sabin; Mehmet Kocak; Alberto Broniscer; Claudia M Hillenbrand; Zoltán Patay
Journal:  Neuroradiology       Date:  2010-09-28       Impact factor: 2.804

6.  Improving contrast to noise ratio of resonance frequency contrast images (phase images) using balanced steady-state free precession.

Authors:  Jongho Lee; Masaki Fukunaga; Jeff H Duyn
Journal:  Neuroimage       Date:  2010-10-30       Impact factor: 6.556

7.  Magnetic resonance fingerprinting based on realistic vasculature in mice.

Authors:  Philippe Pouliot; Louis Gagnon; Tina Lam; Pramod K Avti; Chris Bowen; Michèle Desjardins; Ashok K Kakkar; Eric Thorin; Sava Sakadzic; David A Boas; Frédéric Lesage
Journal:  Neuroimage       Date:  2016-12-31       Impact factor: 6.556

8.  Sensitivity of MRI resonance frequency to the orientation of brain tissue microstructure.

Authors:  Jongho Lee; Karin Shmueli; Masaki Fukunaga; Peter van Gelderen; Hellmut Merkle; Afonso C Silva; Jeff H Duyn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-02       Impact factor: 11.205

9.  Susceptibility gradient quantization by MRI signal response mapping (SIRMA) to dephaser.

Authors:  F Franconi; C Chapon; J J Le Jeune; P Richomme; L Lemaire
Journal:  Med Phys       Date:  2010-02       Impact factor: 4.071

10.  Detection of cerebral microbleeds with quantitative susceptibility mapping in the ArcAbeta mouse model of cerebral amyloidosis.

Authors:  Jan Klohs; Andreas Deistung; Ferdinand Schweser; Joanes Grandjean; Marco Dominietto; Conny Waschkies; Roger M Nitsch; Irene Knuesel; Jürgen R Reichenbach; Markus Rudin
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-17       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.